1-4 of 4
T. Prebet
Close
Sort by
Journal Articles

Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM

C. Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, Francois Dreyfus, Bruno Quesnel, Agnes Guerci, E. Raffoux, S. Brechignac, D. Vassilieff, T. Prebet, Yosr Hicheri, Laurence Legros, MP Chaury, H. Zerazhi, J. Camo, Christian Berthou, M. Hacini, Anne-Laure Taksin, Jacques Delaunay, B. Choufi, Ingrid Lafon, S. Ame, G. Dine, Stéphane Cheze, K. Ghomari, Pierre Fenaux
Journal: Blood
Blood (2008) 112 (11): 2672.
https://doi.org/10.1182/blood.V112.11.2672.2672
Published: 2008
Journal Articles

Donor Response to G-CSF Is the Best Predictive Factor of Extensive Chronic Graft-Versus-Host Disease after Non Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.

N. Dhedin, MD, T. Prebet, MD, D. Rea, MD, PHD, M.L. Tanguy, M. Kuentz, MD, N. Piard, MD, F. Norol, MD, PHD, J.P. Jouet, MD, Ja Rubeil, MD, R. Tabrizi, MD, B. Rio, MD, B. Lioure, MD, P. Tiberghien, MD, PHD, J.H. Bourrhis, MD, A. Sirvent, MD, P. Bordigoni, MD, D. Blaise, MD, Mauricette Michallet, MD, PHD, J.P. Vernant, MD
Journal: Blood
Blood (2007) 110 (11): 2188.
https://doi.org/10.1182/blood.V110.11.2188.2188
Published: 2007
Journal Articles

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

S. Burcheri, MD, T. Prebet, MD, O. Beyne-Rauzy, MD, R.M. Mbida, MD, N. Hoarau, MD, L. Legros, MD, C. Ravoet, MD, F. Dreyfus, MD, A. Stamatoullas, MD, M.P. Chaury, MD, J. Delaunay, MD, G. Laurent, MD, N. Vey, MD, L. Ades, MD, C. Gardin, MD, Pierre Fenaux, MD
Journal: Blood
Blood (2007) 110 (11): 820.
https://doi.org/10.1182/blood.V110.11.820.820
Published: 2007
Journal Articles

Sustained Effect of First Line Sequential Therapy with Intensive Consolidation Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) after Reduced Intensity Conditioning (RIC) for Patients with Acute Myeloblastic Leukemia (AML) in First Complete Remission (CR1).

Didier Blaise, MD, R. Tabrizi, MD, C. Faucher, MD, Mohamad Mohty, MD, J.O. Bay, MD, J.M. Boiron, MD, G. Marit, MD, S. Furst, MD, A.M. Stoppa, MD, A. Charbonnier, MD, T. Prebet, MD, C. Chabannon, MD, N. Vey
Journal: Blood
Blood (2006) 108 (11): 3000.
https://doi.org/10.1182/blood.V108.11.3000.3000
Published: 2006